Results 241 to 250 of about 6,445,882 (303)

Re‐Purposing Sapropterin (Kuvan) for ACTA2‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an ultra‐rare, ACTA2‐related disorder characterized by severe cerebrovascular disease, aortic aneurysms, and smooth muscle dysfunction. Using molecular dynamics simulations and in silico drug screening, we identified that sapropterin dihydrochloride (Kuvan) is a candidate capable of ...
Moran Hausman‐Kedem, Noa Bielopolski, Vijai Krishnan, Shane Wald‐Altman, Shelly I Shrian, Omer Bar‐Yosef, Livia Kapusta, Claire Shamber, Patricia L. Musolino, Miguel Weil   +9 more
wiley   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine, Fabien Rollot, Romain Casey, Nicolas Collongues, Sandra Vukusic, Guillaume Mathey, Anne Laure Dubessy, Jonathan Ciron, Jérôme De Seze, Aurélie Ruet, Pierre Labauge, Arnaud Kwiatkowski, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun‐Frenay, David Axel Laplaud, Eric Berger, Eric Thouvenot, Jean Pelletier, Abdullatif Al Khedr, Olivier Casez, Bertrand Bourre, Abir Wahab, Laurent Magy, Jean‐Philippe Camdessanché, Ines Doghri, Solène Moulin, Mariana Sarov Rivière, Karolina Hankiewicz, Amélie Dos Santos, Corinne Pottier, Eric Manchon, Jennifer Aboab, Maia Tchikviladze, Thomas David, Gilles Edan, Emmanuelle Le Page, Laure Michel, Anne Kerbrat, OFSEP Investigators   +40 more
wiley   +1 more source

Propagation Mechanisms of Security Risks in Public Data Circulation via Inter-Risk Dependencies: A DSM-Based Network Analysis. [PDF]

Risk Anal
Wang N, Li Y, Mikkonen T, Li W, Cong F.
europepmc   +1 more source

Implications of the new US AI framework in medicine. [PDF]

Commun Med (Lond)
Armoundas AA.
europepmc   +1 more source

AI Therapy Chatbots in Youth With Attention-Deficit/Hyperactivity Disorder: A Nurse-Led, Risk-Tiered Policy Framework. [PDF]

Asian Pac Isl Nurs J
Ishibashi S, Kubota K.
europepmc   +1 more source

Construction strategies and implementation pathways of resilience governance system for care risks in older adult care institutions from a social-ecological perspective. [PDF]

Front Public Health
Li C, Xie Y, Liu W.
europepmc   +1 more source

The Governance Gap: Democratizing Drug Development Through Decision Architecture. [PDF]

Clin Pharmacol Ther
Rayner CR, Martin NE, Smith D, Kruger E, Kirkpatrick CMJ, Pillai GC, Moore K, Nix D, Donini C, Cramer JP, Muniz E, Muniz N, Bos E, McNair D, Bhaskaran S, Sullivan M, Hartman D.   +16 more
europepmc   +1 more source

Navigating regulatory fragmentation in the convergence of synthetic biology, artificial intelligence, and automation. [PDF]

Nat Commun
McLennan RKJ, Freemont PS, Pretorius IS.
europepmc   +1 more source

Corporate governance and internal control: Evidence from local public utilities

, 2008
BOSETTI, Luisa
core  

Some of the next articles are maybe not open access.

Related searches:

Risk governance

Journal of Risk Research, 2011
The term 'governance' has been used in political science to describe the multitude of actors and processes that lead to collective binding decisions. The term 'risk governance' involves the translation of the substance and core principles of governance to the context of risk-related decision-making.
Marjolein van Asselt, Ortwin Renn
exaly   +5 more sources